Dexcom (DXCM) fundamentals: P/E, valuation, undervalued?
Dexcom · Health Care · ref. ETF XLV · price $85.06
In short — Dexcom trades at 33.8× earnings (P/E), 27.2× forward, with a net margin of 20.1 % and revenue growth of +13 %. Read: Cheap for the growth (P/E 27 for ~44% growth (PEG 0.6)).
Is Dexcom stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$85.06+28.5% over range
Oct 14, 25low $54.84 · high $92.34Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
94% recommend buying · 16 analysts
Valuation : Cheap for the growth — P/E 27 for ~44% growth (PEG 0.6)
Valuation
33.8
P/E (price/earnings)
27.2
Forward P/E
0.77
PEG
12.2
Price/book (P/B)
$32.1B
Market cap
2.52
EPS
Profitability & growth
20.1 %
Net margin
+13 %
Revenue growth
+44 %
Earnings growth
$1.4B
Total debt
Dexcom income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $2.9B | $341M | 11.7 % |
| 2023 | $3.6B | $542M | 14.9 % |
| 2024 | $4.0B | $576M | 14.3 % |
| 2025 | $4.7B | $836M | 17.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Dexcom's P/E and is the stock undervalued? What's a good P/E?
Dexcom's P/E is 33.8 (forward 27.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Dexcom profitable?
Dexcom has a net margin of 20.1 % (EPS 2.52). The company is profitable.
Is DXCM stock expensive?
Our read: "Cheap for the growth" — P/E 27 for ~44% growth (PEG 0.6). Cross-check with growth and sector.
💬 A question about Dexcom? The JPI assistant answers using our backtest data.